$ 21.42
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the...
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. Specifically, the stock is overvalued on EV/EBITDA, reasonably pric
Target Price
The average target price of CSTL is 37 and suggests 73% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
